Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it’s a chance to learn about new science and keep tabs on evolving assets. For smaller biotechs, though, it can be three-days of high-pressure networking where a lot is riding on making the right pitch to the...
All content for Beyond Biotech - the podcast from Labiotech is the property of Labiotech and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it’s a chance to learn about new science and keep tabs on evolving assets. For smaller biotechs, though, it can be three-days of high-pressure networking where a lot is riding on making the right pitch to the...
How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes
Beyond Biotech - the podcast from Labiotech
28 minutes
4 days ago
How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes
Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it’s a chance to learn about new science and keep tabs on evolving assets. For smaller biotechs, though, it can be three-days of high-pressure networking where a lot is riding on making the right pitch to the...
Beyond Biotech - the podcast from Labiotech
Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it’s a chance to learn about new science and keep tabs on evolving assets. For smaller biotechs, though, it can be three-days of high-pressure networking where a lot is riding on making the right pitch to the...
